Imaging Endpoints is Helping Sponsors Increase Patient Accrual

We leverage the analysis of FDG-PET images to expand eligibility in clinical trials by providing a means to evaluate disease in patients who are otherwise non-assessable by RECIST. As an example, bone-only disease can be a leading reason for classification as non-measurable by RECIST, but FDG-PET allows for the detection and assessment of these lesions and may be utilized to accrue and follow such patients. Imaging Endpoints provides real-time (24 hour) eligibility reads for global trials.

We congratulate Dr. Ulaner on his important publication showing how FDG PET can improve patient accrual, see https://clincancerres.aacrjournals.org/content/25/24/7381.abstract.